As reported by EU-Startups, Helsinki-based AIATELLA has secured €2 million in funding to advance the development and deployment of its Automated Image Measurement (AIM) technology.
Backed by Nordic Science Investments, Specialist VC, Harjavalta Ventures, and Business Finland, the funding will support clinical trials and the rollout of portable ultrasound-based screening tools capable of detecting carotid artery narrowing in just minutes. CEO Jack Parker emphasizes the urgent need to relieve overburdened radiology departments and deliver earlier, more accurate diagnoses to prevent catastrophic events like strokes.
Source: helsinkismart.fi.
Founded in 2022, AIATELLA’s mission is to overhaul conventional radiology by replacing time-intensive manual imaging workflows with high-speed, AI-powered automation. Its AIM platform, compatible with MRI, CT, and ultrasound imaging, can process and quantify vascular abnormalities up to 100 times faster than existing methods.
The technology is already helping clinicians identify asymptomatic cases of cardiovascular narrowing, and early pilot programs have shown promising real-world impacts in both Europe and North America. With the ability to streamline interpretation and standardize measurement quality, AIATELLA’s platform supports both efficiency and equity in cardiovascular care.
The company’s broader vision includes scaling preventative screening across populations, enabling early detection even before symptoms arise. With cardiovascular disease still the world’s leading cause of death—despite being largely preventable—AIATELLA’s portable solution could become a key tool in public health. The startup also places a strong focus on addressing disparities in how heart disease manifests across genders and ethnicities, aiming to build a more inclusive and data-driven approach to cardiovascular diagnostics.
